Rapport Therapeutics Inc (RAPP) has a current Price-to-Book (P/B) ratio of 2.62. Compared to its 3-year average P/B ratio of 1.95, the current P/B ratio is approximately 34.31% higher. Relative to its 5-year average P/B ratio of 1.95, the current P/B ratio is about 34.31% higher. Rapport Therapeutics Inc (RAPP) has a Forward Free Cash Flow (FCF) yield of approximately -5.81%. Compared to its 3-year average FCF yield of -10.37%, the current FCF yield is approximately -43.94% lower. Relative to its 5-year average FCF yield of -10.37%, the current FCF yield is about -43.94% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RAPP competitors is 16.73, providing a benchmark for relative valuation. Rapport Therapeutics Inc Corp (RAPP.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RAPP increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RAPP in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RAPP currently overvalued or undervalued?

What is Rapport Therapeutics Inc (RAPP) fair value?

RAPP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Rapport Therapeutics Inc (RAPP) is between to according to relative valuation method.

How does RAPP's valuation metrics compare to the industry average?

The average P/S ratio for RAPP's competitors is 16.73, providing a benchmark for relative valuation. Rapport Therapeutics Inc Corp (RAPP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Rapport Therapeutics Inc (RAPP) as of Mar 03 2026?

As of Mar 03 2026, Rapport Therapeutics Inc (RAPP) has a P/B ratio of 2.62. This indicates that the market values RAPP at 2.62 times its book value.

What is the current FCF Yield for Rapport Therapeutics Inc (RAPP) as of Mar 03 2026?

As of Mar 03 2026, Rapport Therapeutics Inc (RAPP) has a FCF Yield of -5.81%. This means that for every dollar of Rapport Therapeutics Inc's market capitalization, the company generates -5.81 cents in free cash flow.

What is the current Forward P/E ratio for Rapport Therapeutics Inc (RAPP) as of Mar 03 2026?

As of Mar 03 2026, Rapport Therapeutics Inc (RAPP) has a Forward P/E ratio of -8.70. This means the market is willing to pay $-8.70 for every dollar of Rapport Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Rapport Therapeutics Inc (RAPP) as of Mar 03 2026?

As of Mar 03 2026, Rapport Therapeutics Inc (RAPP) has a Forward P/S ratio of 0.00. This means the market is valuing RAPP at $0.00 for every dollar of expected revenue over the next 12 months.

RAPP Valuation